Maxim Group set a $3.00 price target on Pluristem Therapeutics, Inc. (NASDAQ:PSTI) in a research note published on Wednesday morning. The brokerage currently has a buy rating on the biotechnology company’s stock.

Several other equities research analysts have also recently weighed in on PSTI. HC Wainwright reaffirmed a buy rating and issued a $3.50 price target on shares of Pluristem Therapeutics in a research note on Tuesday, September 19th. ValuEngine raised Pluristem Therapeutics from a strong sell rating to a sell rating in a research note on Monday, October 2nd. Zacks Investment Research cut Pluristem Therapeutics from a hold rating to a sell rating in a research note on Friday, September 22nd. Finally, Seaport Global Securities reissued a buy rating and issued a $5.00 target price on shares of Pluristem Therapeutics in a research note on Friday, October 6th. Two investment analysts have rated the stock with a sell rating and four have assigned a buy rating to the stock. The company currently has an average rating of Hold and a consensus target price of $4.38.

COPYRIGHT VIOLATION WARNING: “Pluristem Therapeutics, Inc. (PSTI) Given a $3.00 Price Target by Maxim Group Analysts” was originally published by Watch List News and is the property of of Watch List News. If you are viewing this piece of content on another website, it was copied illegally and republished in violation of international copyright & trademark legislation. The original version of this piece of content can be accessed at https://www.watchlistnews.com/pluristem-therapeutics-inc-psti-given-a-3-00-price-target-by-maxim-group-analysts-2/1674029.html.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in PSTI. Heritage Investors Management Corp purchased a new position in Pluristem Therapeutics during the 3rd quarter valued at approximately $113,000. Jane Street Group LLC boosted its holdings in shares of Pluristem Therapeutics by 62.4% in the 1st quarter. Jane Street Group LLC now owns 108,830 shares of the biotechnology company’s stock worth $134,000 after purchasing an additional 41,796 shares during the period. Finally, Renaissance Technologies LLC boosted its holdings in shares of Pluristem Therapeutics by 9.1% in the 1st quarter. Renaissance Technologies LLC now owns 1,553,800 shares of the biotechnology company’s stock worth $1,911,000 after purchasing an additional 129,000 shares during the period. Institutional investors and hedge funds own 4.54% of the company’s stock.

Pluristem Therapeutics Company Profile

Pluristem Therapeutics Inc is a developer of placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. The Company’s lead indications are critical limb ischemia (CLI), recovery after surgery for femoral neck fracture and acute radiation syndrome.

Receive News & Ratings for Pluristem Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pluristem Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.